Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 21;13:4648. doi: 10.1038/s41598-023-31198-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Monovalent SARS-CoV-2 RBD-cCPE and bivalent SARS-CoV-2 RBD-cCPE/Influenza H1-HA₁-cCPE vaccines induces CD4 and CD8 T-cell responses against recombinant SARSCoV-2 RBD or influenza H1-HA₁. Monovalent SARS-CoV-2 RBD-cCPE and bivalent SARS-CoV-2 RBD-cCPE/Influenza H1-HA₁-cCPE vaccines induce CD4 and CD8 T-cell responses against recombinant SARS-CoV-2 RBD or influenza H1-HA₁ protein. (a) Mice were prime-boost immunized intranasally (days 0, 21) with either monovalent non-targeted RBD, strain Wuhan-Hu-1 (group #1), M-cell targeted RBD (RBD-cCPE, group #7), both adjuvanted with Riboxxim or PBS (group #9). On day 28 bulk splenocytes (Bulk, squares) or splenocytes MACS-depleted for either CD8 (CD4, rhombus) or MACS-depleted for CD4 (CD8, triangles) were analyzed for IFNγ production upon restimulation with recombinant RBD or recombinant ACE2 as control (Neg control, dots) in ELISPOT. Data are presented as means + SD. Statistics: two-way ANOVA followed by Tukey’s multiple comparisons test with ns not significant; ***p ≤ 0.001; ****p < 0.0001. The individual CD4 and CD8 T-cell responses were statistically significantly different between group #1 and #7 (p = 0.0018 and p = 0.0051, respectively) and between group #2 and group #7 (p = 0.0014 and p = 0.0203, respectively), by one-way ANOVA. (b) Mice were prime-boost immunized intranasally with bivalent SARS-CoV-2 RBD-cCPE/influenza H1-HA₁-cCPE, adjuvanted with Riboxxim. On day 28 splenocytes were analyzed for IFNγ production upon restimulation with recombinant RBD (dots) derived from SARS-CoV-2 strain Wuhan-Hu-1 or an H1-HA₁ consensus sequence (squares) protein in ELISPOT. Data are presented as means + SD. Statistics: Unpaired t test, ns not significant.